Artwork

Konten disediakan oleh Dr. Jason Edwards. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Dr. Jason Edwards atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !

Revolutionary Advancements in Blood Cancer Treatment with Dr. Mark Fesler

30:40
 
Bagikan
 

Manage episode 439356417 series 3599583
Konten disediakan oleh Dr. Jason Edwards. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Dr. Jason Edwards atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

Discover the revolutionary advancements in blood cancer treatment with Dr. Mark Fesler, a leading hematologist and oncologist at St. Luke's. We promise you'll gain a comprehensive understanding of the intricate phases of clinical trials, from safety assessments to efficacy evaluations. Dr. Fesler sheds light on the transformative shift from traditional cytotoxic drugs to cutting-edge immunotherapies, including checkpoint inhibitors, chimeric antigen T cells, and the promising bispecific antibodies that are changing the landscape of cancer care.
Navigate the complexities of clinical trials through the lens of Nassim Nicholas Taleb's "Black Swan" concept, appreciating the delicate balance of risk and benefit in drug development. We'll uncover the significant breakthroughs in bispecific antibodies for blood cancers and discuss the ethical considerations of fast-tracking treatments for patients facing limited life expectancy. Additionally, we tackle the reproducibility crisis in clinical trials, highlighting the importance of reliable and robust findings in ensuring patient safety and treatment efficacy.
Look to the future as we explore the expanding potential of bispecific therapies beyond blood cancers to solid tumors like breast, prostate, and lung cancer. Dr. Fesler shares insights on ongoing clinical trials at St. Luke's and emphasizes the move towards outpatient treatments and earlier lines of therapy. Learn about the specific immune-related cancers that show promising responses to these therapies and find out how patients can get involved in these groundbreaking studies. Join us in celebrating the relentless efforts of healthcare professionals and researchers driving innovation and improving patient outcomes in hematology and oncology.

  continue reading

Chapter

1. Advancements in Blood Cancer Treatment (00:00:00)

2. Risks and Benefits in Clinical Trials (00:11:21)

3. Expanding Use of Bispecific Therapies (00:22:29)

4. Advancing Hematology and Oncology (00:29:29)

12 episode

Artwork
iconBagikan
 
Manage episode 439356417 series 3599583
Konten disediakan oleh Dr. Jason Edwards. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Dr. Jason Edwards atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

Discover the revolutionary advancements in blood cancer treatment with Dr. Mark Fesler, a leading hematologist and oncologist at St. Luke's. We promise you'll gain a comprehensive understanding of the intricate phases of clinical trials, from safety assessments to efficacy evaluations. Dr. Fesler sheds light on the transformative shift from traditional cytotoxic drugs to cutting-edge immunotherapies, including checkpoint inhibitors, chimeric antigen T cells, and the promising bispecific antibodies that are changing the landscape of cancer care.
Navigate the complexities of clinical trials through the lens of Nassim Nicholas Taleb's "Black Swan" concept, appreciating the delicate balance of risk and benefit in drug development. We'll uncover the significant breakthroughs in bispecific antibodies for blood cancers and discuss the ethical considerations of fast-tracking treatments for patients facing limited life expectancy. Additionally, we tackle the reproducibility crisis in clinical trials, highlighting the importance of reliable and robust findings in ensuring patient safety and treatment efficacy.
Look to the future as we explore the expanding potential of bispecific therapies beyond blood cancers to solid tumors like breast, prostate, and lung cancer. Dr. Fesler shares insights on ongoing clinical trials at St. Luke's and emphasizes the move towards outpatient treatments and earlier lines of therapy. Learn about the specific immune-related cancers that show promising responses to these therapies and find out how patients can get involved in these groundbreaking studies. Join us in celebrating the relentless efforts of healthcare professionals and researchers driving innovation and improving patient outcomes in hematology and oncology.

  continue reading

Chapter

1. Advancements in Blood Cancer Treatment (00:00:00)

2. Risks and Benefits in Clinical Trials (00:11:21)

3. Expanding Use of Bispecific Therapies (00:22:29)

4. Advancing Hematology and Oncology (00:29:29)

12 episode

Semua episode

×
 
Loading …

Selamat datang di Player FM!

Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.

 

Panduan Referensi Cepat